$VNDA
Vanda Pharmaceuticals Inc.

2020 Q2 Form 10-Q Financial Statement

#000134717820000024 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $62.21M $59.06M
YoY Change 5.33% 24.73%
Cost Of Revenue $5.850M $6.368M
YoY Change -8.13% 22.16%
Gross Profit $55.99M $52.31M
YoY Change 7.03% 25.33%
Gross Profit Margin 90.01% 88.58%
Selling, General & Admin $33.92M $31.47M
YoY Change 7.78% 12.55%
% of Gross Profit 60.58% 60.15%
Research & Development $12.90M $10.95M
YoY Change 17.84% 10.99%
% of Gross Profit 23.04% 20.93%
Depreciation & Amortization $600.0K $800.0K
YoY Change -25.0% 0.0%
% of Gross Profit 1.07% 1.53%
Operating Expenses $46.82M $42.42M
YoY Change 10.38% 12.14%
Operating Profit $9.171M $9.895M
YoY Change -7.32% 152.88%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.920M $1.650M
YoY Change 16.36% 108.86%
Pretax Income $11.09M $11.54M
YoY Change -3.94% 145.56%
Income Tax $2.400M $18.00K
% Of Pretax Income 21.64% 0.16%
Net Earnings $8.714M $11.53M
YoY Change -24.4% 149.97%
Net Earnings / Revenue 14.01% 19.52%
Basic Earnings Per Share $0.16 $0.22
Diluted Earnings Per Share $0.16 $0.21
COMMON SHARES
Basic Shares Outstanding 54.50M shares 53.10M shares
Diluted Shares Outstanding 55.08M shares 54.58M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $339.8M $280.2M
YoY Change 21.3% 21.17%
Cash & Equivalents $95.31M $46.54M
Short-Term Investments $244.5M $233.6M
Other Short-Term Assets $15.00M $10.70M
YoY Change 40.19% -9.32%
Inventory $1.384M $1.057M
Prepaid Expenses
Receivables $24.59M $23.89M
Other Receivables $0.00 $0.00
Total Short-Term Assets $380.9M $315.8M
YoY Change 20.6% 17.35%
LONG-TERM ASSETS
Property, Plant & Equipment $3.744M $4.240M
YoY Change -11.7% -11.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $12.50M
YoY Change
Other Assets $89.10M $4.400M
YoY Change 1925.0% 18.92%
Total Long-Term Assets $125.8M $56.68M
YoY Change 121.89% 67.58%
TOTAL ASSETS
Total Short-Term Assets $380.9M $315.8M
Total Long-Term Assets $125.8M $56.68M
Total Assets $506.6M $372.5M
YoY Change 36.01% 22.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.400M $5.700M
YoY Change -5.26% 21.28%
Accrued Expenses $23.00M $56.90M
YoY Change -59.58% 41.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $61.59M $62.58M
YoY Change -1.57% 33.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.735M $221.0K
YoY Change 685.07% -95.37%
Total Long-Term Liabilities $1.735M $221.0K
YoY Change 685.07% -95.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.59M $62.58M
Total Long-Term Liabilities $1.735M $221.0K
Total Liabilities $75.05M $75.79M
YoY Change -0.98% 46.72%
SHAREHOLDERS EQUITY
Retained Earnings -$211.5M -$325.3M
YoY Change -34.99% -8.04%
Common Stock $642.5M $621.6M
YoY Change 3.35% 2.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $431.6M $296.7M
YoY Change
Total Liabilities & Shareholders Equity $506.6M $372.5M
YoY Change 36.01% 22.96%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $8.714M $11.53M
YoY Change -24.4% 149.97%
Depreciation, Depletion And Amortization $600.0K $800.0K
YoY Change -25.0% 0.0%
Cash From Operating Activities $24.00M $20.60M
YoY Change 16.5% 368.18%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$300.0K
YoY Change -33.33% -98.8%
Acquisitions
YoY Change
Other Investing Activities $2.900M -$11.40M
YoY Change -125.44% -85.02%
Cash From Investing Activities $2.700M -$11.70M
YoY Change -123.08% -88.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.600M 3.400M
YoY Change 5.88% 36.0%
NET CHANGE
Cash From Operating Activities 24.00M 20.60M
Cash From Investing Activities 2.700M -11.70M
Cash From Financing Activities 3.600M 3.400M
Net Change In Cash 30.30M 12.30M
YoY Change 146.34% -113.03%
FREE CASH FLOW
Cash From Operating Activities $24.00M $20.60M
Capital Expenditures -$200.0K -$300.0K
Free Cash Flow $24.20M $20.90M
YoY Change 15.79% -29.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001347178
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28000 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34186
dei Entity Registrant Name
EntityRegistrantName
VANDA PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0491827
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20037
dei Entity Address City Or Town
EntityAddressCityOrTown
Washington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DC
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45072000 USD
dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Pennsylvania Avenue NW
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300 E
dei City Area Code
CityAreaCode
202
dei Local Phone Number
LocalPhoneNumber
734-3400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
VNDA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54651399 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95305000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
244544000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
267057000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24587000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26367000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
1384000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1140000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15041000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14500000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
380861000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
354136000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3744000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3864000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10601000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11180000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22298000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23037000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
85558000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
87680000 USD
CY2020Q2 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
3569000 USD
CY2019Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
3851000 USD
CY2020Q2 us-gaap Assets
Assets
506631000 USD
CY2019Q4 us-gaap Assets
Assets
483748000 USD
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
28398000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
27590000 USD
CY2020Q2 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
33194000 USD
CY2019Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
31915000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
61592000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59505000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11720000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12455000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1735000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
843000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
75047000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
72803000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54628336 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54628336 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53549612 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53549612 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
54000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
642398000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
631307000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
596000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
249000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-211465000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220665000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
431584000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
410945000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
506631000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
483748000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62207000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59060000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120207000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
106773000 USD
CY2020Q2 us-gaap Revenues
Revenues
62207000 USD
CY2019Q2 us-gaap Revenues
Revenues
59060000 USD
us-gaap Revenues
Revenues
120207000 USD
us-gaap Revenues
Revenues
106773000 USD
CY2020Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
5847000 USD
CY2019Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6368000 USD
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
11054000 USD
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
11481000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12903000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10950000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28430000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24228000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33917000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31468000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
70938000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
62497000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
369000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
379000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
739000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
759000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
53036000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
49165000 USD
us-gaap Costs And Expenses
CostsAndExpenses
111161000 USD
us-gaap Costs And Expenses
CostsAndExpenses
98965000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
9171000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
9895000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
9046000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
7808000 USD
CY2020Q2 us-gaap Other Income
OtherIncome
1918000 USD
CY2019Q2 us-gaap Other Income
OtherIncome
1649000 USD
us-gaap Other Income
OtherIncome
3284000 USD
us-gaap Other Income
OtherIncome
3134000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
11089000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
11544000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
12330000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
10942000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2375000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3130000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
11526000 USD
us-gaap Net Income Loss
NetIncomeLoss
9200000 USD
us-gaap Net Income Loss
NetIncomeLoss
10914000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54501308 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53101499 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54153812 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52928101 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55081397 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54579982 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54975771 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54932932 shares
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
11526000 USD
us-gaap Net Income Loss
NetIncomeLoss
9200000 USD
us-gaap Net Income Loss
NetIncomeLoss
10914000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
10000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
6000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-3000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
2000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-252000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
245000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
453000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
383000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-57000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
103000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-185000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
251000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
347000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
385000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8529000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11777000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9547000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11299000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
410945000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
479000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3944000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
486000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
532000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
416386000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3600000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3069000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-185000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
431584000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275422000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
179000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3282000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-612000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
134000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
278405000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3411000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3101000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
11526000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
251000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
296694000 USD
us-gaap Net Income Loss
NetIncomeLoss
9200000 USD
us-gaap Net Income Loss
NetIncomeLoss
10914000 USD
us-gaap Depreciation
Depreciation
694000 USD
us-gaap Depreciation
Depreciation
672000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7013000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6383000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
420000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1848000 USD
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
229000 USD
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
739000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
759000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2019000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-695000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-740000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1672000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4851000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
591000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-681000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-10000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
191000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
883000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5159000 USD
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
1414000 USD
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
2038000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23099000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
30158000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
583000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
657000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
151124000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
191293000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
174739000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
143745000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23032000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48205000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4079000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3590000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4079000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3590000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50233000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14462000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45650000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61749000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95883000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47287000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95305000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46543000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95883000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47287000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
770000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62207000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59060000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120207000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
106773000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
243784000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
244544000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
266750000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
313000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
267057000 USD
CY2020Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
287062000 USD
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
274027000 USD
CY2019Q4 vnda Inventory
Inventory
3964000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1384000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1140000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
1384000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1140000 USD
CY2020Q2 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
745000 USD
CY2019Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
659000 USD
CY2020Q2 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
1247000 USD
CY2019Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
1109000 USD
CY2020Q2 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
552000 USD
CY2019Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
1056000 USD
CY2020Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
2544000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
2824000 USD
CY2020Q2 vnda Inventory
Inventory
3928000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000 USD
CY2020Q2 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
6459000 USD
CY2019Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
5893000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6286000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5376000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5536000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6597000 USD
CY2020Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5418000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5904000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2181000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2147000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2518000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1673000 USD
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
28398000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
27590000 USD
vnda Percentage Of Future Sublicense Fees Payable
PercentageOfFutureSublicenseFeesPayable
mid-twenties
vnda Agreements For Clinical And Marketing Services Termination Notice Period
AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
P90D
CY2020Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
500000 USD
CY2020Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
1000000.0 USD
CY2020Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
500000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
10000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
13000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
586000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
236000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
596000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
249000 USD
vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
vnda Share Based Compensation Arrangementby Share Based Payment Annual Award Vesting Period Employeesand New Directors
ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
P4Y
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3101000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7013000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6383000 USD
vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25
vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75
vnda Sharebased Compensation Arrangementby Share Based Payment Award Options Vesting Period Number Of Equal Monthly Installments
SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
36 installment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
545104 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.16
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4100000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3600000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3069000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M4D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0128
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0248
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3100000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
11526000 USD
us-gaap Net Income Loss
NetIncomeLoss
9200000 USD
us-gaap Net Income Loss
NetIncomeLoss
10914000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54501308 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53101499 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54153812 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52928101 shares
CY2020Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
580089 shares
CY2019Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1478483 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
821959 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2004831 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55081397 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54579982 shares
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54975771 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54932932 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3813824 shares
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2294277 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3454524 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1415953 shares

Files In Submission

Name View Source Status
0001347178-20-000024-index-headers.html Edgar Link pending
0001347178-20-000024-index.html Edgar Link pending
0001347178-20-000024.txt Edgar Link pending
0001347178-20-000024-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20200630.htm Edgar Link pending
vnda-20200630.xsd Edgar Link pending
vnda-20200630_cal.xml Edgar Link unprocessable
vnda-20200630_def.xml Edgar Link unprocessable
vnda-20200630_htm.xml Edgar Link completed
vnda-20200630_lab.xml Edgar Link unprocessable
vnda-20200630_pre.xml Edgar Link unprocessable
vndaex311630202010q.htm Edgar Link pending
vndaex312630202010q.htm Edgar Link pending
vndaex321630202010q.htm Edgar Link pending